

FEB 15 2001

TECH CENTER 1600/2900

structure of the peptide, oligopeptide, or protein inhibitor
is such that one or more arginine groups are available to the
nitric oxide synthase.

Please cancel claim 2.

3. (Amended)

The method of claim 1, wherein the [inhibitor] peptide,
oligopeptide, or protein is [N-methyl-L-arginine] selected
from the group consisting of L-Arginine, Poly-Arginine, BK,
Des-Arg1-BK, Des-Arg9-BK, BK fragment 1-7, BK fragment 2-7,
[Lys1]-BK, Lys-BK, Ile-Ser-BK, and Met-Lys-BK.

Handwritten notes:
 - "protein" with an arrow pointing to "Poly-Arginine"
 - "O n. act." with an arrow pointing to "BK fragment 2-7"
 - "O no act." with an arrow pointing to "Met-Lys-BK"
 - "new" with a double underline and an arrow pointing to the entire list of compounds

Please cancel claims 4, 7 and 8.

10. (Amended)

A method of preventing or treating a nitric oxide-
 mediated disease or condition in a mammalian subject
 comprising administering to the subject in need of such
 prevention or treatment [a therapeutically effective amount]
from about 20-500 µg/kg of a peptide, oligopeptide, or protein
 [inhibitor of] that acts as a substrate for or an inhibitor of
 nitric oxide synthase.

Handwritten notes:
 - "with" with an arrow pointing to "preventing or treating"
 - "B" with a circle around it, pointing to "that acts as a substrate..."

Please cancel claim 12.

RECEIVED

FEB 15 2001

13. (Amended)

sub
B⁴
a⁴

The method of claim 10, wherein the [inhibitor] peptide, oligopeptide, or protein is [N^ω-methyl-L-arginine] selected from the group consisting of L-Arginine, Poly-Arginine, BK, Des-Arg1-BK, Des-Arg9-BK, BK fragment 1-7, BK fragment 2-7, [Lys1]-BK, Lys-BK, Ile-Ser-BK, and Met-Lys-BK.

Please cancel claim 14.

16. (New)

a⁵

sub
B⁵

A method of regulating or controlling nitric oxide production in a mammalian subject comprising administering to the mammal from about 20-500 µg/kg of a peptide, oligopeptide, or protein that acts as a substrate for a nitric oxide synthase, whereby the tertiary structure of the peptide, oligopeptide, or protein inhibitor is such that one or more arginine groups are available to the nitric oxide synthase, said peptide, oligopeptide or protein being selected from the group consisting of L-Arginine, Poly-Arginine, BK, Des-Arg1-BK, Des-Arg9-BK, BK fragment 1-7, BK fragment 2-7, [Lys1]-BK, Lys-BK, Ile-Ser-BK, and Met-Lys-BK.

REMARKS

I. Claim Rejections - 35 U.S.C. 112, First Paragraph

Claims 1-15 were rejected under 35 U.S.C. § 112, first paragraph, as being based on a disclosure that is not